Andere talen Takeda Pharmaceutical Company Limited Mexican S.E.

Aandelen

TAK N

US8740602052

slotkoers Mexican S.E. Andere beurzen 00:00:00 13-03-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
240,5 ^MXN	-1,84%		-.--%	+0,33%

15:21	Sectorupdate: Gezondheidszorgaandelen dalen premarket maandag	MT
14:13	Ovid zoekt afstand van epilepsiemedicijn nadat Takeda rapporteert dat Fase 3 eindpunten niet gehaald zijn -- Pre-Bell aandelen dalen	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	15:35
Sector Update: Health Care Stocks Decline Premarket Monday	15:21
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	14:59
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	14:13
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	14:00
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	13:32
Takeda's seizure drug fails to meet main goal in late-stage studies	13:07
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	12:55
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	12:50
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	12:46
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	12:45
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	14/06
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	14/06
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	14/06
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees	11/06
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	11/06
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	11/06
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen	10/06
TAKEDA PHARMACEUTICAL : Form 6 K	10/06
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	07/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Takeda Pharmaceutical Company Limited Mexican S.E.

Aandelen

TAK N

US8740602052

Andere talen

Filters